City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Vincent Chung, MD  
Search results:  11  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-11 Trials Jump to page:

COH Protocol Number: 17493 ClinicalTrials.gov Number: NCT03201458

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-165, NCI#10139: A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

COH Protocol Number: 17363 ClinicalTrials.gov Number: NCT03331562

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  A SU2C Catalyst Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda) With or Without a Vitamin D Receptor Agonist Paricalcitol (Zemplar) in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (With no Further Improvement in Their Tumor)

COH Protocol Number: 17345 ClinicalTrials.gov Number: NCT03199586

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)

COH Protocol Number: 17332 ClinicalTrials.gov Number: NCT03355066

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

COH Protocol Number: 17210 ClinicalTrials.gov Number: NCT02964013

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

COH Protocol Number: 17179 ClinicalTrials.gov Number: NCT03267940

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

COH Protocol Number: 16215 ClinicalTrials.gov Number: NCT02030067

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies

COH Protocol Number: 15320

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  The Total Cancer Care Protocol: A Lifetime Partnership with Patients of the City of Hope

COH Protocol Number: 15213 ClinicalTrials.gov Number: NCT02453620

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-83, NCI#9844: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors

COH Protocol Number: 12217 ClinicalTrials.gov Number: NCT01638533

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-72, NCI #9008: A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

COH Protocol Number: 12115 ClinicalTrials.gov Number: NCT01534598

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-70, NCI #9127: Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors

 
Results per page: 25 50 100 All 1-11 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.